Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Sci Adv ; 6(5): eaax2285, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-32064333

RESUMEN

To be optimally effective, peptide-based vaccines need to be administered with adjuvants. Many currently available adjuvants are toxic, not biodegradable; they invariably invoke adverse reactions, including allergic responses and excessive inflammation. A nontoxic, biodegradable, biocompatible, self-adjuvanting vaccine delivery system is urgently needed. Herein, we report a potent vaccine delivery system fulfilling the above requirements. A peptide antigen was coupled with poly-hydrophobic amino acid sequences serving as self-adjuvanting moieties using solid-phase synthesis, to produce fully defined single molecular entities. Under aqueous conditions, these molecules self-assembled into distinct nanoparticles and chain-like aggregates. Following subcutaneous immunization in mice, these particles successfully induced opsonic epitope-specific antibodies without the need of external adjuvant. Mice immunized with entities bearing 15 leucine residues were able to clear bacterial load from target organs without triggering the release of soluble inflammatory mediators. Thus, we have developed a well-defined and effective self-adjuvanting delivery system for peptide antigens.


Asunto(s)
Sistemas de Liberación de Medicamentos , Inflamación/prevención & control , Vacunas de Subunidad/farmacología , Vacunas/farmacología , Adyuvantes Inmunológicos/farmacología , Aminoácidos/química , Aminoácidos/inmunología , Animales , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacología , Epítopos/efectos de los fármacos , Epítopos/inmunología , Humanos , Inmunidad Mucosa/inmunología , Inflamación/inmunología , Ratones , Nanopartículas/química , Vacunas/química , Vacunas/inmunología , Vacunas de Subunidad/química , Vacunas de Subunidad/inmunología
2.
Blood Transfus ; 12 Suppl 1: s204-8, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23149140

RESUMEN

BACKGROUND: It has been demonstrated recently that α1,3-galactosidase from Bacteroides fragilis can efficiently convert human group B red blood cells (RBC) to group O cells. In addition, in vitro data indicated that the enzymatic conversion process did not affect the physiological or metabolic parameters of the RBC. The aim of this study was to investigate the lifespan of enzyme- treated RBC in vivo in the circulation. MATERIALS AND METHODS: This was an experimental, randomised study. The rat was selected as the experimental subject because it expresses α-1,3galactosyl on its RBC. The efficiency of Galα1,3Gal epitope removal from RBC treated with α1,3-galactosidase was tested before the transfusion experiment to track the survival of RBC in the circulation. The animals were divided into three groups and injected via the tail vein with native, mock-treated or enzyme-treated RBC labelled with fluorescein isothiocyanate. The survival rates of the fluorescently labelled RBC were monitored by flow cytometry. RESULTS: Flow cytometry showed that α-galactosidase (0.02 mg/mL for RBC with a haematocrit of 30%) efficiently removed Galα1,3Gal epitopes from rat erythrocytes, although small amounts of remaining Galα1,3Gal epitopes were still detected. The in vivo data demonstrated that the half-life of enzyme-treated RBC was a little shorter than that of native RBC. However, the 24-hour survival fractions of native, mock-treated and enzyme-treated RBC were virtually identical. Most importantly, the enzyme-treated RBC, like the native RBC, were still detectable 35 days after transfusion. DISCUSSION: Our results indicate that α-glycosidase treatment had little effect on the in vivo survival kinetics of RBC. These data add further support to the feasibility of translating enzymatic conversion technology into clinical practice.


Asunto(s)
Proteínas Bacterianas/farmacología , Bacteroides fragilis/enzimología , Transfusión de Eritrocitos , Eritrocitos/efectos de los fármacos , Galactosidasas/farmacología , Sistema del Grupo Sanguíneo ABO/química , Animales , Tipificación y Pruebas Cruzadas Sanguíneas , Supervivencia Celular , Evaluación Preclínica de Medicamentos , Epítopos/efectos de los fármacos , Estudios de Factibilidad , Citometría de Flujo , Galactosidasas/aislamiento & purificación , Humanos , Masculino , Lectinas de Plantas/análisis , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley
4.
Arzneimittelforschung ; 52(6): 500-5, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12109052

RESUMEN

Pharmacological effects of mistletoe extracts are determined by the concentration of three toxic lectins: mistletoe lectin I (MLI, or viscumin), MLII, MLIII. These proteins, as well as ricin, belong to ribosome-inactivating proteins type 2 (RIP2). However, the extracts from the plant Ricinus communis, containing ricin, are highly toxic. Ricin is about 30 times more effective in cell culture than viscumin. The dissociation of subunits and the transmembrane transport of catalytic subunit into the cytoplasm are needed to obtain the cytotoxic effect of RIP2. In this paper, hybridomas producing monoclonal antibodies against catalytic subunits of ricin and viscumin are described. Monoclonal antibodies against different epitopes, including one localized in intra-subunit area of catalytic subunits of ricin and viscumin, do not inhibit the enzymatic activity of these proteins in cell-free system. These hybridomas are resistant to the cytotoxic action of native toxins. Protective effect of antibodies are about the same for both toxins, though the dissociation of the subunits of ricin is more effective. The causes of the differences in activity of plant toxins as pharmacological agents, and the importance of above mentioned epitopes for neutralizing antibodies at the clinical applications of mistletoe extracts are discussed.


Asunto(s)
Antineoplásicos Fitogénicos/toxicidad , Preparaciones de Plantas , Proteínas de Plantas , Ricina/toxicidad , Toxinas Biológicas/toxicidad , Animales , Anticuerpos Monoclonales/biosíntesis , Anticuerpos Monoclonales/química , Células Productoras de Anticuerpos/efectos de los fármacos , Antineoplásicos Fitogénicos/inmunología , Biotina/química , Supervivencia Celular/efectos de los fármacos , Ditiotreitol/farmacología , Epítopos/efectos de los fármacos , Hibridomas/efectos de los fármacos , Técnicas para Inmunoenzimas , Ratones , Proteínas Inactivadoras de Ribosomas Tipo 2 , Ricina/inmunología , Sales de Tetrazolio , Tiazoles , Toxinas Biológicas/inmunología
5.
Biosci Biotechnol Biochem ; 62(12): 2334-40, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9972259

RESUMEN

The effects of arginine on cell proliferation and subsequent T helper (Th) 1 and Th 2 cytokine synthesis by murine Peyer's patch (PP) Th cells in vitro and the influence of arginine on the induction of antigen-specific mucosal and systemic immune responses in vivo were examined. When the PP T cells were stimulated with the anti-alpha beta T cell receptor (TCR) antibody in the presence of different concentrations of arginine, a higher proliferative response was observed in the culture with an optimal concentration of arginine compared with that with a minimum amount of this amino acid. The concentration of cytokines in the supernatant, the number of cytokine-producing cells and the cytokine-specific mRNA expression of PP T cells were also increased in a dose-dependent fashion. Furthermore, when mice fed on an arginine-supplemented liquid diet were orally immunized with tetanus toxoid plus cholera toxin as a mucosal adjuvant, a higher level of antigen-specific fecal IgA was observed when compared with the response in mice fed on an arginine-free diet. Taken together, these results suggest that arginine enhanced antigen-specific mucosal immune response resulting from the supporting activation of cell proliferation and subsequent cytokine synthesis of PP Th cells.


Asunto(s)
Arginina/farmacología , Citocinas/biosíntesis , Epítopos/efectos de los fármacos , Ganglios Linfáticos Agregados/inmunología , Alimentación Animal , Animales , Arginina/inmunología , Toxina del Cólera/inmunología , Citocinas/análisis , Replicación del ADN/inmunología , Ensayo de Inmunoadsorción Enzimática , Epítopos/inmunología , Heces/química , Inmunidad Mucosa , Inmunoglobulina A/sangre , Activación de Linfocitos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ganglios Linfáticos Agregados/citología , Ganglios Linfáticos Agregados/efectos de los fármacos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Conteo por Cintilación , Toxoide Tetánico/inmunología , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células Th2/efectos de los fármacos , Células Th2/inmunología
6.
Scand J Immunol ; 37(4): 490-8, 1993 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7682335

RESUMEN

Five monoclonal antibodies (MoAbs) were raised against porcine soluble CD44. The MoAbs recognized the same antigen on the surface of porcine lymphocytes as was recognized by anti-human CD44 MoAb Hermes-1, but identified five different epitopes. They bound to most porcine leucocytes but not to red cells. The epitopes were susceptible to treatment with papain or bromelain, whereas trypsinization of porcine leucocytes only reduced the antigen density. The epitopes seem to be co-expressed among various lymphoid tissues. The MoAbs also cross-reacted to various degrees with leucocytes of humans, dogs, sheep, cattle, goats and horses, suggesting that the corresponding epitopes are differentially conserved among species.


Asunto(s)
Anticuerpos Monoclonales , Epítopos/inmunología , Receptores Mensajeros de Linfocitos/inmunología , Animales , Anticuerpos Monoclonales/química , Bromelaínas/farmacología , Reacciones Cruzadas , Epítopos/efectos de los fármacos , Hibridomas , Papaína/farmacología , Pruebas de Precipitina , Porcinos
7.
Artículo en Ruso | MEDLINE | ID: mdl-1379773

RESUMEN

Purified staphylococcal toxoid is capable of partially preventing the development of antigen-specific (induced by the supraoptimal dose of sheep red blood cells) and antigen-nonspecific (induced by Tahyna virus) defects of humoral immune response, as well as abolishing these defects. The presence and manifestation of the correction of virus-induced immunodeficiency is determined by the dose of the toxoid and the interval between the injections of purified staphylococcal toxoid and the infective agent.


Asunto(s)
Virus de la Encefalitis de California , Encefalitis de California/terapia , Epítopos/efectos de los fármacos , Enfermedades del Sistema Inmune/terapia , Toxoide Estafilocócico/uso terapéutico , Animales , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/inmunología , Relación Dosis-Respuesta Inmunológica , Evaluación Preclínica de Medicamentos , Encefalitis de California/etiología , Encefalitis de California/inmunología , Epítopos/inmunología , Enfermedades del Sistema Inmune/etiología , Enfermedades del Sistema Inmune/inmunología , Inmunización/métodos , Ratones , Ratones Endogámicos CBA , Toxoide Estafilocócico/aislamiento & purificación , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA